151 related articles for article (PubMed ID: 6284643)
21. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
Weinberg A; Merigan TC
J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
[TBL] [Abstract][Full Text] [Related]
22. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
[TBL] [Abstract][Full Text] [Related]
23. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
24. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
[TBL] [Abstract][Full Text] [Related]
25. Crossed immunoelectrophoretic studies of the solubility immunogenicity of herpes simplex virus antigens.
Vestergaard BF; Bjerrum OJ; Norrild B; Grauballe PC
J Virol; 1977 Oct; 24(1):82-90. PubMed ID: 198588
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins.
Martin S; Cantin E; Rouse BT
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1359-70. PubMed ID: 2543783
[TBL] [Abstract][Full Text] [Related]
27. Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment.
Mukhlis FA; Jennings R; Stephenson TJ; Quasim T; Potter CW
Vaccine; 1986 Sep; 4(3):191-6. PubMed ID: 3020821
[TBL] [Abstract][Full Text] [Related]
28. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans.
Mertz GJ; Peterman G; Ashley R; Jourden JL; Salter D; Morrison L; McLean A; Corey L
J Infect Dis; 1984 Aug; 150(2):242-9. PubMed ID: 6088648
[TBL] [Abstract][Full Text] [Related]
29. Destabilization of target-sensitive immunoliposomes by antigen binding--a rapid assay for virus.
Ho RJ; Rouse BT; Huang L
Biochem Biophys Res Commun; 1986 Jul; 138(2):931-7. PubMed ID: 3017345
[TBL] [Abstract][Full Text] [Related]
30. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.
Yasukawa M; Zarling JM
J Immunol; 1984 Nov; 133(5):2736-42. PubMed ID: 6207243
[TBL] [Abstract][Full Text] [Related]
31. Enhanced Immunogenicity and Protective Efficacy of a
Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
mSphere; 2019 May; 4(3):. PubMed ID: 31043512
[No Abstract] [Full Text] [Related]
32. Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB.
Kitamura K; Namazue J; Campo-Vera H; Ogino T; Yamanishi K
Virology; 1986 Feb; 149(1):74-82. PubMed ID: 2418583
[TBL] [Abstract][Full Text] [Related]
33. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
Berman PW; Gregory T; Crase D; Lasky LA
Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
[TBL] [Abstract][Full Text] [Related]
34. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response.
Mitchell BM; Stevens JG
J Immunol; 1996 Jan; 156(1):246-55. PubMed ID: 8598469
[TBL] [Abstract][Full Text] [Related]
35. Immune response to herpes simplex virus in patients with recurrent herpes labialis. II. Relationship between interferon production and cytotoxic responses.
Tsutsumi H; Bernstein JM; Riepenhoff-Talty M; Ogra PL
Pediatr Res; 1986 Sep; 20(9):905-8. PubMed ID: 3018660
[TBL] [Abstract][Full Text] [Related]
36. A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2.
Watari E; Dietzschold B; Szokan G; Heber-Katz E
J Exp Med; 1987 Feb; 165(2):459-70. PubMed ID: 3029270
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
39. Characterization of "modified-self"-induced specific antibody hyporesponsiveness to herpes simplex virus.
Wilson LA; Thompson JJ; Ohkawa S; Scott DW
Viral Immunol; 1992; 5(2):113-22. PubMed ID: 1377470
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
